SCHEMBL2016284

SCHEMBL2016284

O=C(Oc1ccccc1)C1CCCN1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.49
DPP8 Q6V1X1 1/20 0.49
ANPEP P15144 1/20 0.48
ELANE P08246 3/20 0.47
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.44
ALDH1A1 P00352 3/20 0.44
RAB9A P51151 1/20 0.44
SCN4A P35499 1/20 0.42
CTSC P53634 1/20 0.42
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23356900 1.00 DPP4 (0.49) DPP4DPP8ANPEPELANEHTR2C
SCHEMBL4447785 1.00 DPP4 (0.49) DPP4DPP8ANPEPELANEHTR2C
Hydrochloric Acid SCHEMBL10521985 0.98 DPP4 (0.50) DPP4DPP8ANPEPELANEHTR2C
SCHEMBL15155167 0.88 ELANE (0.46) DPP4DPP8ANPEPELANEHTR2C
SCHEMBL28789042 0.84 HTT (0.46) HTR2CSMN1; SMN2HTTKMT2ATDP1
SCHEMBL29035303 0.84 HTT (0.46) DPP4HTR2CHTR2BSMN1; SMN2HTT
SCHEMBL3060268 0.84 HTT (0.46) DPP4DPP8ELANEHTR2CHTR2B
SCHEMBL16197773 0.84 HTT (0.46) DPP4DPP8ELANEHTR2CHTR2B
SCHEMBL18295372 0.84 HTT (0.46) DPP4HTR2CHTR2BSMN1; SMN2HTT
SCHEMBL27740311 0.84 TDP1 (0.46) DPP4DPP8ANPEPELANEHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 US disclosed
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-02 US disclosed
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-02 US disclosed
US-20230286973-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2023-09-14 US disclosed
US-11612663-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-28 US disclosed
US-20220313867-A1 ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-10-06 US disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed
US-11246961-B2 Engineered scaffolds for vascularized tissue repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-15 US disclosed
EP-3426700-B1 ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR UNIV CALIFORNIA (US) 2021-12-15 EP disclosed
CN-110498808-B Intermediate for synthesizing (2S,3R) -3-substituted phenyl pyrrolidine-2-carboxylic acid and preparation method and application thereof 浙江晖石药业有限公司 2021-11-05 CN disclosed
US-9073974-B2 RGD-containing cyclic peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-07-07 US disclosed
US-20150165026-A1 SINGLET OXYGEN-LABILE LINKERS AND METHODS OF PRODUCTION AND USE THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2015-06-18 US disclosed
US-20150165026-A1 SINGLET OXYGEN-LABILE LINKERS AND METHODS OF PRODUCTION AND USE THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2015-06-18 US disclosed
WO-2013163321-A1 SINGLET OXYGEN-LABILE LINKERS AND METHODS OF PRODUCTION AND USE THEREOF YOU YOUNGJAE (US) 2013-10-31 WO disclosed
US-20130172270-A1 RGD-CONTAINING CYCLIC PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-07-04 US disclosed
US-20130129972-A1 Porous Thin Films THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-05-23 US disclosed
WO-2011079015-A1 RGD-CONTAINING CYCLIC PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-30 WO disclosed
EP-1135398-A1 CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION Monsanto Technology LLC (US) 2001-09-26 EP disclosed
US-6218563-B1 Cyanophosphonamides and method for preparation MONSANTO COMPANY 2001-04-17 US disclosed
WO-2000032611-A1 CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION MONSANTO TECHNOLOGY LLC (US) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, PDGFRB, TEK DPP4 1591/4885DPP8 1261/4885ANPEP 960/4885
US-20220313867-A1 ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR FLT4, FLT1, KDR DPP4 1022/4885DPP8 1831/4885ANPEP 194/4885
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK DPP4 1591/4885DPP8 1261/4885ANPEP 960/4885
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G DPP4 2157/4885DPP8 1605/4885ANPEP 719/4885
US-20230286973-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G DPP4 2343/4885DPP8 1769/4885ANPEP 604/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA DPP4 2242/4885DPP8 1566/4885ANPEP 380/4885
US-11246961-B2 Engineered scaffolds for vascularized tissue repair FLT4, FLT1, KDR DPP4 1022/4885DPP8 1831/4885ANPEP 194/4885
US-11612663-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK DPP4 1591/4885DPP8 1261/4885ANPEP 960/4885
US-20150165026-A1 SINGLET OXYGEN-LABILE LINKERS AND METHODS OF PRODUCTION AND USE THEREOF PPOX, DUOX1, PAICS DPP4 4430/4885DPP8 3786/4885ANPEP 1862/4885
US-20130172270-A1 RGD-CONTAINING CYCLIC PEPTIDES ITGAV, ITGB3, ITGAL DPP4 1930/4885DPP8 3002/4885ANPEP 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.